NASDAQ:BDSI

BioDelivery Sciences International Competitors

$3.42
-0.05 (-1.44 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$3.37
Now: $3.42
$3.51
50-Day Range
$3.45
MA: $3.83
$4.41
52-Week Range
$3.04
Now: $3.42
$5.45
Volume1.40 million shs
Average Volume1.25 million shs
Market Capitalization$344.95 million
P/E Ratio24.43
Dividend YieldN/A
Beta0.72

Competitors

BioDelivery Sciences International (NASDAQ:BDSI) Vs. JNJ, PFE, MRK, ABBV, LLY, and BMY

Should you be buying BDSI stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to BioDelivery Sciences International, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), and Bristol-Myers Squibb (BMY).

Johnson & Johnson (NYSE:JNJ) and BioDelivery Sciences International (NASDAQ:BDSI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Insider & Institutional Ownership

67.3% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 67.4% of BioDelivery Sciences International shares are owned by institutional investors. 0.3% of Johnson & Johnson shares are owned by insiders. Comparatively, 8.6% of BioDelivery Sciences International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Johnson & Johnson and BioDelivery Sciences International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson031102.79
BioDelivery Sciences International01402.80

Johnson & Johnson presently has a consensus target price of $182.6154, indicating a potential upside of 12.56%. BioDelivery Sciences International has a consensus target price of $8.15, indicating a potential upside of 138.30%. Given BioDelivery Sciences International's stronger consensus rating and higher probable upside, analysts clearly believe BioDelivery Sciences International is more favorable than Johnson & Johnson.

Valuation and Earnings

This table compares Johnson & Johnson and BioDelivery Sciences International's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.06 billion5.21$15.12 billion$8.6818.69
BioDelivery Sciences International$111.39 million3.10$-15,310,000.00$0.1034.20

Johnson & Johnson has higher revenue and earnings than BioDelivery Sciences International. Johnson & Johnson is trading at a lower price-to-earnings ratio than BioDelivery Sciences International, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Johnson & Johnson has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, BioDelivery Sciences International has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Profitability

This table compares Johnson & Johnson and BioDelivery Sciences International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson21.01%34.64%13.40%
BioDelivery Sciences International10.16%25.04%9.89%

Summary

Johnson & Johnson beats BioDelivery Sciences International on 9 of the 14 factors compared between the two stocks.

Pfizer (NYSE:PFE) and BioDelivery Sciences International (NASDAQ:BDSI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Insider & Institutional Ownership

67.4% of Pfizer shares are owned by institutional investors. Comparatively, 67.4% of BioDelivery Sciences International shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 8.6% of BioDelivery Sciences International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Pfizer and BioDelivery Sciences International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer010302.23
BioDelivery Sciences International01402.80

Pfizer presently has a consensus target price of $38.5714, indicating a potential upside of 0.00%. BioDelivery Sciences International has a consensus target price of $8.15, indicating a potential upside of 138.30%. Given BioDelivery Sciences International's stronger consensus rating and higher probable upside, analysts clearly believe BioDelivery Sciences International is more favorable than Pfizer.

Valuation and Earnings

This table compares Pfizer and BioDelivery Sciences International's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion4.16$16.27 billion$2.9513.07
BioDelivery Sciences International$111.39 million3.10$-15,310,000.00$0.1034.20

Pfizer has higher revenue and earnings than BioDelivery Sciences International. Pfizer is trading at a lower price-to-earnings ratio than BioDelivery Sciences International, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Pfizer has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, BioDelivery Sciences International has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Profitability

This table compares Pfizer and BioDelivery Sciences International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer17.85%24.88%9.32%
BioDelivery Sciences International10.16%25.04%9.89%

Summary

BioDelivery Sciences International beats Pfizer on 8 of the 14 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and BioDelivery Sciences International (NASDAQ:BDSI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Merck & Co., Inc. and BioDelivery Sciences International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021102.85
BioDelivery Sciences International01402.80

Merck & Co., Inc. presently has a consensus target price of $96.2727, indicating a potential upside of 24.27%. BioDelivery Sciences International has a consensus target price of $8.15, indicating a potential upside of 138.30%. Given BioDelivery Sciences International's higher probable upside, analysts clearly believe BioDelivery Sciences International is more favorable than Merck & Co., Inc..

Valuation and Earnings

This table compares Merck & Co., Inc. and BioDelivery Sciences International's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.19$9.84 billion$5.1914.93
BioDelivery Sciences International$111.39 million3.10$-15,310,000.00$0.1034.20

Merck & Co., Inc. has higher revenue and earnings than BioDelivery Sciences International. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than BioDelivery Sciences International, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

72.9% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 67.4% of BioDelivery Sciences International shares are owned by institutional investors. 0.3% of Merck & Co., Inc. shares are owned by insiders. Comparatively, 8.6% of BioDelivery Sciences International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Merck & Co., Inc. and BioDelivery Sciences International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.24.33%53.83%16.83%
BioDelivery Sciences International10.16%25.04%9.89%

Risk & Volatility

Merck & Co., Inc. has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, BioDelivery Sciences International has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Summary

Merck & Co., Inc. beats BioDelivery Sciences International on 10 of the 14 factors compared between the two stocks.

BioDelivery Sciences International (NASDAQ:BDSI) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings for BioDelivery Sciences International and AbbVie, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioDelivery Sciences International01402.80
AbbVie121302.75

BioDelivery Sciences International currently has a consensus price target of $8.15, indicating a potential upside of 138.30%. AbbVie has a consensus price target of $115.75, indicating a potential upside of 7.27%. Given BioDelivery Sciences International's stronger consensus rating and higher probable upside, research analysts plainly believe BioDelivery Sciences International is more favorable than AbbVie.

Valuation & Earnings

This table compares BioDelivery Sciences International and AbbVie's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioDelivery Sciences International$111.39 million3.10$-15,310,000.00$0.1034.20
AbbVie$33.27 billion5.72$7.88 billion$8.9412.07

AbbVie has higher revenue and earnings than BioDelivery Sciences International. AbbVie is trading at a lower price-to-earnings ratio than BioDelivery Sciences International, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

67.4% of BioDelivery Sciences International shares are held by institutional investors. Comparatively, 67.5% of AbbVie shares are held by institutional investors. 8.6% of BioDelivery Sciences International shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares BioDelivery Sciences International and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioDelivery Sciences International10.16%25.04%9.89%
AbbVie18.16%439.24%13.22%

Volatility and Risk

BioDelivery Sciences International has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

Summary

AbbVie beats BioDelivery Sciences International on 10 of the 14 factors compared between the two stocks.

BioDelivery Sciences International (NASDAQ:BDSI) and Eli Lilly and (NYSE:LLY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings for BioDelivery Sciences International and Eli Lilly and, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioDelivery Sciences International01402.80
Eli Lilly and041102.73

BioDelivery Sciences International currently has a consensus price target of $8.15, indicating a potential upside of 138.30%. Eli Lilly and has a consensus price target of $196.40, indicating a potential upside of 3.78%. Given BioDelivery Sciences International's stronger consensus rating and higher probable upside, research analysts plainly believe BioDelivery Sciences International is more favorable than Eli Lilly and.

Valuation & Earnings

This table compares BioDelivery Sciences International and Eli Lilly and's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioDelivery Sciences International$111.39 million3.10$-15,310,000.00$0.1034.20
Eli Lilly and$22.32 billion8.13$8.32 billion$6.0431.33

Eli Lilly and has higher revenue and earnings than BioDelivery Sciences International. Eli Lilly and is trading at a lower price-to-earnings ratio than BioDelivery Sciences International, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

67.4% of BioDelivery Sciences International shares are held by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are held by institutional investors. 8.6% of BioDelivery Sciences International shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares BioDelivery Sciences International and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioDelivery Sciences International10.16%25.04%9.89%
Eli Lilly and24.01%166.45%15.18%

Volatility and Risk

BioDelivery Sciences International has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500.

Summary

Eli Lilly and beats BioDelivery Sciences International on 10 of the 14 factors compared between the two stocks.

BioDelivery Sciences International (NASDAQ:BDSI) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings for BioDelivery Sciences International and Bristol-Myers Squibb, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioDelivery Sciences International01402.80
Bristol-Myers Squibb021312.94

BioDelivery Sciences International currently has a consensus price target of $8.15, indicating a potential upside of 138.30%. Bristol-Myers Squibb has a consensus price target of $74.60, indicating a potential upside of 13.96%. Given BioDelivery Sciences International's higher probable upside, research analysts plainly believe BioDelivery Sciences International is more favorable than Bristol-Myers Squibb.

Valuation & Earnings

This table compares BioDelivery Sciences International and Bristol-Myers Squibb's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioDelivery Sciences International$111.39 million3.10$-15,310,000.00$0.1034.20
Bristol-Myers Squibb$26.15 billion5.59$3.44 billion$4.6913.96

Bristol-Myers Squibb has higher revenue and earnings than BioDelivery Sciences International. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than BioDelivery Sciences International, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

67.4% of BioDelivery Sciences International shares are held by institutional investors. Comparatively, 72.4% of Bristol-Myers Squibb shares are held by institutional investors. 8.6% of BioDelivery Sciences International shares are held by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares BioDelivery Sciences International and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioDelivery Sciences International10.16%25.04%9.89%
Bristol-Myers Squibb-0.11%27.48%10.77%

Volatility and Risk

BioDelivery Sciences International has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Summary

Bristol-Myers Squibb beats BioDelivery Sciences International on 10 of the 15 factors compared between the two stocks.


BioDelivery Sciences International Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.7$162.24-1.1%$427.13 billion$82.06 billion25.51Upcoming Earnings
Pfizer logo
PFE
Pfizer
2.3$38.57-2.5%$215.13 billion$51.75 billion24.88Analyst Revision
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.2$77.47-1.0%$196.03 billion$46.84 billion17.14Increase in Short Interest
Analyst Revision
News Coverage
AbbVie logo
ABBV
AbbVie
2.8$107.91-0.9%$190.44 billion$33.27 billion22.81Analyst Revision
Eli Lilly and logo
LLY
Eli Lilly and
2.1$189.25-1.8%$181.49 billion$22.32 billion30.92Analyst Revision
News Coverage
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$65.46-1.6%$146.23 billion$26.15 billion-595.04Analyst Upgrade
Decrease in Short Interest
Analyst Revision
Zoetis logo
ZTS
Zoetis
2.2$167.63-1.3%$79.62 billion$6.26 billion49.74Increase in Short Interest
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$41.87-0.5%$25.42 billionN/A0.00Dividend Announcement
Insider Selling
Increase in Short Interest
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$93.27-0.3%$20.90 billion$1.30 billion25.48Insider Selling
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$168.90-0.3%$9.51 billion$2.16 billion53.28Analyst Report
Perrigo logo
PRGO
Perrigo
2.3$41.62-1.1%$5.56 billion$4.84 billion-693.55
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00-1.9%$3.46 billion$114.62 million-7.66Analyst Report
Insider Selling
News Coverage
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07-5.2%$2.77 billion$421.03 million22.21Analyst Report
Insider Selling
High Trading Volume
News Coverage
Gap Up
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77-0.7%$2.67 billion$306.49 million25.58
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.70-0.5%$1.68 billion$392.76 million13.15Analyst Upgrade
Analyst Revision
Endo International logo
ENDP
Endo International
1.3$6.26-3.4%$1.44 billion$2.91 billion-9.21
Omeros logo
OMER
Omeros
1.4$18.37-0.2%$1.14 billion$111.81 million-7.72News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.00-3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
Gap Down
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$8.01-1.4%$375.61 million$16.54 million-3.26News Coverage
Lannett logo
LCI
Lannett
2.0$4.76-0.2%$197.07 million$545.74 million-6.61
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.28-1.2%$171.45 million$15.96 million-2.59
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$2.99-1.7%$44.61 million$47.53 million-13.59
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.